- Home
- DCOM vs EWTX Comparison
DCOM vs EWTX Comparison
Compare DCOM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- EWTX
- Stock Information
- Founded
- DCOM 1864
- EWTX 2017
- Country
- DCOM United States
- EWTX United States
- Employees
- DCOM N/A
- EWTX N/A
- Industry
- DCOM Major Banks
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- EWTX Health Care
- Exchange
- DCOM Nasdaq
- EWTX Nasdaq
- Market Cap
- DCOM 1.2B
- EWTX 1.2B
- IPO Year
- DCOM 1996
- EWTX 2021
- Fundamental
- Price
- DCOM $26.58
- EWTX $14.58
- Analyst Decision
- DCOM Buy
- EWTX Buy
- Analyst Count
- DCOM 4
- EWTX 8
- Target Price
- DCOM $33.88
- EWTX $40.13
- AVG Volume (30 Days)
- DCOM 268.9K
- EWTX 1.2M
- Earning Date
- DCOM 04-22-2025
- EWTX 05-08-2025
- Dividend Yield
- DCOM 3.76%
- EWTX N/A
- EPS Growth
- DCOM N/A
- EWTX N/A
- EPS
- DCOM 0.62
- EWTX N/A
- Revenue
- DCOM $295,419,000.00
- EWTX N/A
- Revenue This Year
- DCOM $54.60
- EWTX N/A
- Revenue Next Year
- DCOM $15.74
- EWTX N/A
- P/E Ratio
- DCOM $42.53
- EWTX N/A
- Revenue Growth
- DCOM N/A
- EWTX N/A
- 52 Week Low
- DCOM $17.49
- EWTX $10.60
- 52 Week High
- DCOM $37.60
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- DCOM 53.12
- EWTX 41.67
- Support Level
- DCOM $25.92
- EWTX $13.82
- Resistance Level
- DCOM $26.92
- EWTX $17.30
- Average True Range (ATR)
- DCOM 0.80
- EWTX 1.02
- MACD
- DCOM 0.22
- EWTX 0.32
- Stochastic Oscillator
- DCOM 86.12
- EWTX 30.43
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.